Related Experiment Video
Updated: Aug 12, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study
M Dougados1, B Combe, T Beveridge
1Hôpital Cochin, René Descartes University, Paris, France.
Arthritis and Rheumatism
|September 1, 1992
Summary
IX 207-887 (10-methoxy-4H-benzo(4,5)cyclohepta-(1,2-b)thiophene-4-yliden acetic acid) demonstrated efficacy and acceptable safety in rheumatoid arthritis patients, showing significant improvement in clinical and laboratory parameters compared to placebo.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Interleukin-1 (IL-1) plays a key role in RA pathogenesis.
- IX 207-887, a novel compound, inhibits IL-1 release and has shown promise in animal models of RA.
Purpose of the Study:
- To evaluate the efficacy and safety of IX 207-887 in patients with rheumatoid arthritis.
- To assess the dose-response relationship of IX 207-887 treatment.
Main Methods:
- A 16-week, double-blind, placebo-controlled trial was conducted.
- 16 weeks, double-blind, placebo-controlled trial.
- Patients received either placebo, IX 207-887 at 800 mg daily, or IX 207-887 at 1,200 mg daily (20 patients per group).
Main Results:
- Intent-to-treat analysis revealed statistically significant differences in clinical and laboratory parameters between groups.
- A higher proportion of patients responded to IX 207-887 compared to placebo (45% and 55% for 800 mg and 1,200 mg groups, respectively, vs. 10% for placebo).
- Adverse events included skin rash, intestinal disturbances, hepatitis, and meningitis, with higher incidence in the IX 207-887 groups.
Conclusions:
- IX 207-887 is an effective slow-acting drug for rheumatoid arthritis.
- The tolerability of IX 207-887 was found to be acceptable in RA patients.
- Further investigation into the safety profile and long-term efficacy of IX 207-887 is warranted.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...